Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.

Smith HA, Maricque BB, Eberhardt J, Petersen B, Gulley JL, Schlom J, McNeel DG.

J Biomed Biotechnol. 2011;2011:454861. doi: 10.1155/2011/454861.

2.

Immunotherapy for prostate cancer.

Fong L, Small EJ.

Semin Oncol. 2003 Oct;30(5):649-58. Review.

PMID:
14571412
3.

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

Antonarakis ES, Drake CG.

Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0. Review.

4.

Immunotherapy for prostate cancer.

Fong L, Small EJ.

Curr Urol Rep. 2006 May;7(3):239-46. Review.

PMID:
16630528
5.

Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.

Hwang C, Sanda MG.

Curr Opin Mol Ther. 1999 Aug;1(4):471-9. Review.

PMID:
11713762
6.

DNA vaccines for the treatment of prostate cancer.

Alam S, McNeel DG.

Expert Rev Vaccines. 2010 Jul;9(7):731-45. doi: 10.1586/erv.10.64. Review.

PMID:
20624047
7.

Biomarkers for the development of cancer vaccines: current status.

Copier J, Whelan M, Dalgleish A.

Mol Diagn Ther. 2006;10(6):337-43. Review.

PMID:
17154650
8.

The potential of DNA vaccination against tumor-associated antigens for antitumor therapy.

Haupt K, Roggendorf M, Mann K.

Exp Biol Med (Maywood). 2002 Apr;227(4):227-37. Review.

PMID:
11910045
9.

Prostate cancer vaccines: current status and future potential.

Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D.

BioDrugs. 2008;22(2):71-84. Review.

PMID:
18345705
10.

Immunotherapy for prostate cancer.

Fong L, Small EJ.

Curr Oncol Rep. 2007 May;9(3):226-33. Review.

PMID:
17430695
11.

[Active immunotherapy of prostate cancer with a focus on dendritic cells].

Thomas-Kaskel AK, Veelken H.

Actas Urol Esp. 2007 Jun;31(6):668-79. Review. Spanish.

PMID:
17896564
12.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

13.

Prostate cancer vaccines in clinical trials.

Lubaroff DM.

Expert Rev Vaccines. 2012 Jul;11(7):857-68. doi: 10.1586/erv.12.54. Review.

PMID:
22913261
14.

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG.

Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Review.

PMID:
24332642
15.

TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.

Salazar-Onfray F, Pereda C, Reyes D, López MN.

Biol Res. 2013;46(4):431-40. doi: 10.4067/S0716-97602013000400014. Review.

16.

Cancer vaccines: current directions and perspectives in prostate cancer.

Mohebtash M, Gulley JL, Madan RA, Ferrara T, Arlen PM.

Curr Opin Mol Ther. 2009 Feb;11(1):31-6. Review.

17.

[Vaccine therapy of prostate cancer].

Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D.

Aktuelle Urol. 2005 Sep;36(5):407-16. Review. German.

PMID:
16163603
18.

Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.

Slovin SF.

Clin Adv Hematol Oncol. 2007 Dec;5(12):972-80. Review.

PMID:
18277959
19.

Prostate cancer vaccines.

Michael A, Relph K, Annels N, Pandha H.

Expert Rev Vaccines. 2013 Mar;12(3):253-62. doi: 10.1586/erv.13.27. Review.

PMID:
23496665
20.

Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.

Pavlenko M, Leder C, Pisa P.

Expert Rev Vaccines. 2005 Jun;4(3):315-27. Review.

PMID:
16026247

Supplemental Content

Support Center